BioCentury
ARTICLE | Clinical News

Genentech's Tecentriq meets in third Phase III for first-line NSCLC

June 1, 2018 6:06 PM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III IMpower130 trial as first-line treatment of stage IV non-squamous non-small cell lung cancer (NSCLC).

The open-label, international trial enrolled 724 patients and compared Tecentriq plus carboplatin and Abraxane nab-paclitaxel vs. carboplatin and Abraxane alone. Genentech did not disclose detailed data, but said it plans to share the results with global health authorities and present them at an oncology meeting...